摘要
Lung cancer is the leading cause of cancer death in China1.Generally,65%-70%of lung cancer patients are already at an advanced,inoperable stage at diagnosis.Therefore,there has been a surge in drug development to address the unmet medical needs of lung cancer.In recent years,benefiting from the precise molecular classification of lung cancer,the number of clinical trials testing drugs in lung cancer has increased rapidly in China,enhancing R&D capacities and the impactful regulatory reform.It thus has led to significant improvements in drug accessibility.
